Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor

Soft Tissue Sarcoma Companies

ID: MRFR/HC/3862-CR
184 Pages
Vikita Thakur
Last Updated: February 16, 2025
Soft tissue sarcomas are a group of rare cancers that develop in the soft tissues of the body, including muscles, fat, blood vessels, nerves, and connective tissues. Companies involved in the development of treatments for soft tissue sarcomas may focus on various approaches, including pharmaceuticals, targeted therapies, and supportive care.
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Soft Tissue Sarcoma Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)6.72%
2024 Market Size$ 1.4 Billion
2025 Market Size$ 1.49 Billion
2035 Market Size$ 2.86 Billion
Key Players
Bristol Myers Squibb
Novartis
Merck & Co
Boehringer Ingelheim
Eli Lilly and Company
Pfizer
Opportunities
  • Advancements in Diagnostic Techniques
  • Emergence of Novel Therapeutic Agents
  • Increased Investment in Cancer Research

Top Industry Leaders in the Soft Tissue Sarcoma Market

Soft Tissue Sarcoma Market
ย 

Latestย Soft Tissue Sarcomaย  Companiesย Updates:

Incyte Corporation acquires Epizyme: This December 2023 acquisition strengthens Incyte's oncology pipeline, adding Epizyme's targeted therapy for STS with EZH2 mutations.

Bayer acquires BlueRock Therapeutics: This October 2023 acquisition expands Bayer's cell and gene therapy portfolio, potentially leading to new treatment options for STS in the future.

This December 2023 news demonstrates FT515's potential in treating advanced STS with FGFR3 mutations, opening doors for further clinical development.

FDA grants Breakthrough Therapy Designation to larotrectinib (Loxo Oncology): This January 2024 designation expedites the development and review process for larotrectinib in patients with STS harboring NTRK gene fusions.

List ofย Soft Tissue Sarcomaย Key companies in the market:

  • GlaxoSmithKline plc (U.K)
  • Eli Lilly and Company (U.S.)
  • Pfizer Inc. (U.S.)
  • Bristol-Myers Squibb (U.S.)
  • Switzerland) Inc. (U.S.)
  • Johnson & Johnson Services Inc. (U.S.)